Advanced Urothelial Carcinoma
Conditions
Brief summary
To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with Albumin-bound paclitaxel in the treatment of Advanced urothelial carcinoma
Detailed description
This trial is designed to first include 6 subjects to confirm the dose safety. If the toxicity is intolerable, the dose of chemotherapeutic drugs will be reduced depending on the toxicity for further exploration.If it was tolerated, the recommended dose was determined, and the dose was extended. 14 patients were enrolled to further observe the safety and efficacy.
Interventions
Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
Sponsors
Lee's Pharmaceutical Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years old; * Pathologically confirmed urothelial carcinoma; * Terminal patients who have not received treatment or for the first time recurrence more than 6 months after the end of adjuvant chemotherapy after surgery; * Evaluable lesions based on RECIST V1.1; * ECOG score 0-1; * Estimated life expectancy \>3 months; * The function of important organs meets the following requirements; * The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.
Exclusion criteria
* Previously received drugs targeting PD-1, PD-L1, PD-L2 or other treatments targeting T cell costimulation or checkpoint channels; * Received systemic corticosteroid immunosuppressants 2 weeks before the study; * Suffer from active meningeal metastasis or uncontrolled, untreated brain metastasis; * Severe cardiovascular disease, such as New York Heart Association (New York Heart Association,NYHA standard) Grade 3-4 heart failure, unstable angina pectoris, unstable arrhythmia, or color heart photo indicates LVEF (left ventricular ejection fraction) \< 50%; * Previous hypersensitivity to monoclonal antibodies; * The patient has known, active or suspected autoimmune diseases. The following conditions are allowed: skin diseases that do not require systemic treatment (such as vitiligo, psoriasis), type I diabetes, autoimmune hypothyroidism with hormone replacement therapy; * The study drug suffered from other active malignant tumors within 5 years before the first use of the drug. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., can be included in the group; * Active hepatitis B or C (unless HBV-DNA titer \< 500IU/mL or copy number \< 1000copies/ml, HCV-RNA negative after antiviral treatment can be included in), HIV positive or known history of acquired immunodeficiency syndrome; * Severe infection existed before screening, including but not limited to, infections requiring hospitalization, bacteremia, severe pneumonia, etc; * There has been active pulmonary tuberculosis in the past year, whether treated or not; * Live attenuated vaccine was used within 28 days prior to screening; * Patients who have previously received allogeneic bone marrow transplantation or solid organ transplantation; * Have received any other experimental drug treatment within 28 days prior to signing ICF; * Pregnant or lactating women; * Patients of childbearing age who refuse to use effective contraception; * Other researchers believe that it is not suitable to join the group.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicity (DLT) | 21 days after first dose | Adverse events of level 3 or above related to the study drug occurring within 21 days after the first dose as assessed by CTCAE v5.0. |
| Recommended phase II dose (RP2D) | 21 days after first dose | DLT occurs in no more than 1/6 subjects, this dose is defined as RP2D. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate | 12 months | Percentage of patients in partial and complete response |
| progression free survival | 12 months | time between first dose of study drug to disease progression |
| PD-L1 expression | 12 months | The positive rate of PD-L1 expression in tumor tissue. |
| TMB expression | 12 months | The positive rate of TMB expression in tumor tissue. |
Countries
China
Outcome results
None listed